INTERVENTIONALPROTOCOL REGISTERED2022-002372-36
The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo controlled N-of-1 trials
Insomnia
Locally preserved from EU Clinical Trials Register (EudraCT)Open EU Clinical Trials Register (EudraCT)↗last source update not reported
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- Not reported
- Enrollment
- Not reported
- Start date
- 2024-01-02
- Sponsor
- Wageningen Research Stichting
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
InsomniaInsomnia
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
No structured eligibility criteria were reported.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 7c3b5a5c-beee-4a01-8571-a1341945b32b
- Retrieved
- 14/09/2026, 10:15:29
- SHA-256
- e5eb3bae05f1ebafee20422c714c04f5eb040db58f0570ba1489ee49a6451a1e